- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01723553
Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Alzheimer's disease (AD) is associated with amyloid-related imaging abnormalities (ARIA). Microbleeds (MBs) represent part of the spectrum of ARIA and can be identified as small hypointense lesions on gradient-recalled echo (GRE) T2*-weighted MRI. They are thought to represent hemosiderin deposits (and hence have been classified as ARIA-H1) and occur as a consequence of leakage of blood products out of vessels that have been damaged by deposition of the protein β-amyloid in cerebral vessels; cerebral amyloid angiopathy (CAA). However, it is also possible that cerebrovascular disease could contribute to the presence of MBs in AD. Subjects with MBs are at a greater risk of bleeds which could impact the use of anti-coagulation treatment approaches.
The presence of CAA has been particularly associated with AD and studies have demonstrated that MBs occur in 12-33% of subjects with typical Alzheimer's dementia, with a large proportion of subjects showing multiple MBs. The presence of MBs has been associated with older age and a greater degree of white matter hyperintensities (WMH) in Alzheimer's dementia. The association between MBs and WMH, a marker of cerebrovascular disease, suggests cerebrovascular disease may also play a role in the etiology of MBs in AD. However, approximately 16% of AD subjects do not present with episodic memory loss, but instead display language problems such as poor naming and impaired sentence repetition, or visuospatial and visual perceptual deficits, and are referred to as atypical AD. Since AD is associated with CAA, one would assume that CAA and hence MBs, would also occur in atypical AD, although no studies have assessed MBs in atypical AD.
Amyloid-binding ligands, such as Pittsburgh Compound B (PiB), that can be detected using PET scanning have now been developed and provide an invaluable biomarker to infer the presence of β-amyloid. The presence of CAA has been shown to be associated with elevated PiB uptake, and hence the assessment of PiB-PET in subjects with MBs will provide important information on the association of MBs and β-amyloid deposition in AD.
The goal of the study is to assess the associations between MBs and demographic/clinical features, assess the associations between MBs and imaging features as well as a possible correlate to the number of MBs a subject has in atypical AD.
Patients found to be eligible and willing to enroll in this study will be asked to undergo a Neurologic Examination, Neuropsychometric testing, an MRI scan, and a PiB PET scan of the brain. This will be done over a period of two days at the Mayo Clinic in Rochester, Minnesota.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- over the age of 21
- will have an informant/study partner who will be able to provide independent evaluation of functioning
- must fulfill clinical diagnostic criteria for atypical AD, and hence should either have a chief complaint of difficulty with language and fulfill criteria for logopenic variant of primary progressive aphasia, or present with visuospatial/perceptual deficits and fulfill criteria for posterior cortical atrophy
- speaks English as their primary language (including bilingual patients whose primary language is English)
- agrees to and is eligible to undergo MRI and PET scanning
- if woman of child bearing age, must agree to pregnancy test no more than 48 hours before the PET scans
Exclusion Criteria:
- subjects with concurrent illnesses that could account for the presenting syndrome, such as traumatic brain injury, strokes or developmental syndromes
- subjects meeting criteria for another neurodegenerative disease, particularly typical Alzheimer's dementia
- women that are pregnant or post-partum and breast-feeding
- subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, and if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm)
- subjects will also be excluded if they do not have an informant, do not consent to research or do not complete all components of the study (neurological exam, neuropsychometric tests, MRI, PiB PET)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PiB positron emission tomography (PET)
All subjects will receive PET imaging with C-11 PiB on approximately day 1 or day 2 of study to determine if they have beta-amyloid deposits in their brains.
|
One time intravenous administration of ~740 megabecquerel (MBq) of [N-methyl-C-11]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects with and without microbleeds
Time Frame: up to day 2 of study
|
up to day 2 of study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of white matter hyperintensity burden on MRI and ratio of amyloid burden on PiB PET scan
Time Frame: Study entry, approximately day 1 or day 2 of study
|
Study entry, approximately day 1 or day 2 of study
|
Number of microbleeds per subject
Time Frame: Study entry, approximately day 1 or day 2 of study
|
Study entry, approximately day 1 or day 2 of study
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jennifer Whitwell, PhD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Neurodegenerative Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Dementia
- Tauopathies
- Language Disorders
- Communication Disorders
- Speech Disorders
- Frontotemporal Lobar Degeneration
- Alzheimer Disease
- Aphasia
- Frontotemporal Dementia
- Aphasia, Primary Progressive
- Pick Disease of the Brain
- Anti-Inflammatory Agents
- Corticosterone
Other Study ID Numbers
- 12-007139
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Posterior Cortical Atrophy (PCA)
-
Centre Hospitalier Universitaire de NiceCompleted
-
University of PennsylvaniaCompletedLogopenic Progressive Aphasia | Posterior Cortical Atrophy (PCA) | Alzheimer's Disease, Early OnsetUnited States
-
Mayo ClinicNational Institute on Aging (NIA)RecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Amnestic Mild Cognitive Disorder | Atypical Alzheimer's Disease | Logopenic Progressive Aphasia (LPA) | Posterior Cortical Atrophy (PCA) | Amnestic Disorder | Amnestic SymptomsUnited States
-
Institut National de la Santé Et de la Recherche...France AlzheimerNot yet recruitingAlzheimer Disease, Early Onset | Posterior Cortical AtrophyFrance
-
International Psychoanalytic University BerlinCharite University, Berlin, GermanyTerminatedDream Disorder | Thrombotic Infarction | PCA InfarctGermany
-
Alterman, Modi, & Wolter Ophthalmic Physicians...CompletedCataract | Astigmatism | Cortical Cataract | Nuclear Sclerosis | Posterior Subcapsular CataractUnited States
-
Steve H. Linn, ODCompletedCortical Cataract | Posterior Subcapsular Cataract | Nuclear Sclerosis of the LensUnited States
-
NYU College of DentistryTerminatedBilateral Sinus Pneumatization | Posterior Maxillary Ridge Atrophy Due to ExtractionUnited States
-
Institut National de la Santé Et de la Recherche...CompletedLogopenic Progressive Aphasia | Posterior Cortical Atrophy | Alzheimer's DiseaseFrance
-
Cairo UniversityUnknownAtrophied Posterior MaxillaEgypt
Clinical Trials on C-11 PiB
-
Mayo ClinicEnrolling by invitationParkinson Disease | Semantic Dementia | Behavioral Variant of Frontotemporal Dementia | CBD | Apraxia of Speech | MSA - Multiple System Atrophy | FTD | PPA | PSP | PCA | LPA | Semantic AphasiaUnited States
-
University of Alabama at BirminghamRecruitingAlzheimer DiseaseUnited States
-
Mayo ClinicNational Institute on Aging (NIA)RecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Amnestic Mild Cognitive Disorder | Atypical Alzheimer's Disease | Logopenic Progressive Aphasia (LPA) | Posterior Cortical Atrophy (PCA) | Amnestic Disorder | Amnestic SymptomsUnited States
-
Avid RadiopharmaceuticalsGeneral Electric; American College of Radiology Imaging NetworkCompletedAlzheimer's DiseaseUnited States
-
Mayo ClinicCompletedAlzheimer's DiseaseUnited States
-
Mayo ClinicNational Institute on Aging (NIA)Enrolling by invitationFrontotemporal Dementia | Vascular Dementia | Alzheimer's Disease | Dementia With Lewy BodiesUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Completed
-
Yale UniversityNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)Active, not recruiting
-
National Institute of Mental Health (NIMH)CompletedHealthy | AtherosclerosisUnited States
-
Brigham and Women's HospitalUnknownMultiple SclerosisUnited States